Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.58 |
| ▸ | SCN9A | Q15858 | 15/20 | 0.54 |
| ▸ | BTK | Q06187 | 3/20 | 0.42 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3364741 | 0.77 | SCN4A (0.47) | SCN4ASCN9ABTKHSPB1 | |
| SCHEMBL30098723 | 0.77 | SCN9A (0.56) | SCN9A | |
| SCHEMBL11670068 | 0.77 | SCN4A (0.51) | SCN4ASCN9A | |
| SCHEMBL30098806 | 0.77 | CASP3 (0.50) | SCN9A | |
| SCHEMBL3135431 | 0.76 | SCN9A (0.72) | SCN4ASCN9A | |
| SCHEMBL13168529 | 0.76 | SCN9A (0.72) | SCN4ASCN9A | |
| SCHEMBL3129126 | 0.75 | SCN4A (0.57) | SCN4ASCN9AHSPB1 | |
| SCHEMBL7444775 | 0.74 | SCN9A (0.63) | SCN9A | |
| SCHEMBL13168622 | 0.74 | SCN4A (1.00) | SCN4ASCN9ABTKHSPB1 | |
| SCHEMBL1386035 | 0.74 | SCN4A (1.00) | SCN4ASCN9ABTKHSPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4832647-B2 | — | — | 2011-12-07 | — | — | JP | claimed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | claimed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | claimed |
| EP-1173169-A4 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | claimed |
| US-6737418-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | EURO-CELTIQUE S.A. (LU) | 2004-05-18 | — | — | US | claimed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | claimed |
| JP-2002540155-A | — | — | 2002-11-26 | — | — | JP | claimed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | claimed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | claimed |
| EP-2266960-B1 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO CELTIQUE SA (LU) | 2014-01-22 | — | — | EP | disclosed |
| EP-2266960-A2 | Aryl-substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles as anticonvulsants | EURO-CELTIQUE S.A. (LU) | 2010-12-29 | — | — | EP | disclosed |
| EP-1173169-B1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2010-05-12 | — | — | EP | disclosed |
| EP-1173169-A4 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO CELTIQUE SA (LU) | 2007-04-04 | — | — | EP | disclosed |
| US-6737418-B2 | CENTRAL NERVOUS SYSTEM DISORDERS; ANTICONVULSANTS | EURO-CELTIQUE S.A. (LU) | 2004-05-18 | — | — | US | disclosed |
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | EURO-CELTIQUE S.A. | 2003-04-10 | — | — | US | disclosed |
| US-6414011-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | EURO-CELTIQUE S.A. (LU) | 2002-07-02 | — | — | US | disclosed |
| EP-1173169-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | Euro-Celtique S.A. (LU) | 2002-01-23 | — | — | EP | disclosed |
| WO-2000057877-A1 | ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069292-A1 | Aryl substituted pyrazoles, imidazoles, oxazoles, thiazoles and pyrroles, and the use thereof | GRIK5, GRIN3A, GRIK3 | SCN4A 598/4885SCN9A 671/4885BTK 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.